Loading
154,901 people were randomised to yearly chest X-rays or usual care. After 13 years the number who died of lung cancer was the same in both groups. The test that had been used for decades did not work.
The lung arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, reported by Oken, Hocking, Kvale and colleagues: 154,901 participants aged 55 to 74 randomised between November 1993 and July 2001 at ten United States centres, 77,445 offered annual posteroanterior chest radiographs for four years and 77,456 to usual care, followed for up to 13 years.
PLCO is the control that makes NLST interpretable. NLST compared low-dose computed tomography against chest radiography rather than against nothing, and the reason that was an acceptable design is that PLCO had already established radiography to be no better than usual care.
A negative screening trial that saved a generation from a useless test, and the reason low-dose computed tomography had to be proved separately rather than assumed to work because it saw more.
Shares NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms, Overdiagnosis, NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers, Early detection roadmap: organ screening → blood tests for many cancers and the tag lung-evidence.
Shares NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms, NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers, Early detection roadmap: organ screening → blood tests for many cancers, Low-dose CT lung screening and the tag lung-evidence.
Shares NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers, Low-dose CT lung screening, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late and the tag lung-evidence.
Shares JAMA, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late, Lung cancer (all types) and the tag lung-evidence.
Shares Early detection roadmap: organ screening → blood tests for many cancers, Low-dose CT lung screening, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late and the tag lung-evidence.
Shares Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late, National Cancer Institute (NIH), Lung cancer (all types) and the tag lung-evidence.
Shares Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, Failures are hidden, Lung cancer (all types), Non-small-cell lung cancer and the tag lung-evidence.
Shares Failures are hidden, Lung cancer (all types), Non-small-cell lung cancer and the tag lung-evidence.